A new class of antibiotics.
The team at Recce Pharmaceuticals has produced a new class of antibiotics which show efficacy in destroying a wide range of disease causing gram-positive and gram-negative bacteria and the superbug mutations of these bacteria.
Our new class of antibiotic has been synthesised using a unique and economic method of manufacture.
Unlike current antibiotics which rely on a specific ‘fit’ between the antibiotic and the bacteria causing the disease, Recce antibiotics have been created by a process of synthesis using a patented technique.
Recce antibiotics work by non-specifically attacking the protein outer wall of the target bacteria causing the bacteria to burst and lose their viability.
No new class of human antibiotics has come on to the market since 1987.
Electron microscope images generated by Dr Peta Clode and Lyn Kirilak of the Centre for Microscopy, Characterisation and Analysis, University of Western Australia, demonstrate RECCE® 327’s unique mechanism of action. Application of RECCE® 327 initially weakens the cell walls of the bacteria and within a few hours leads to cell wall collapse and bacterial cell death.
How does Recce’s antibiotics target superbugs?
RECCE® antibiotics non-specifically attack protein in the outer wall of bacteria. Their unique pressure within causes them to burst and lose viability. The protein may mutate as in a superbug – however, as it is still protein, as usual, the RECCE® antibiotics still attack it. Whether it is the normal or superbug form of the bacteria – RECCE® antibiotics still kills it.
There are two important aspects of bacteria:
- They all have an outer wall, always containing protein which strengthens the wall.
- They all have a high internal pressure, caused by internal metabolism. (This pressure may be well over atmospheric pressure – in the order of the normal pressure within a bicycle tyre) - human body cells do not have this internal pressure.